ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,287.60
      -0.24%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.135
      0.00%
      Bitcoin
      63,134.54
      -0.38%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Merus NV (MRUS) Quote

      Merus NV

      Merus NV (MRUS)

      NASDAQ
      49.67
      -1.14
      (-2.24%)
      Closed September 21 4:00PM
      Delayed by 15 minutes
      49.67
      -0.10
      (-0.20%)
      After Hours: 6:47PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      49.67
      Bid
      47.71
      Ask
      50.88
      Volume
      1,095,747
      49.50 Day's Range 51.275
      19.805 52 Week Range 61.61
      Market Cap
      3.388B
      Previous Close
      50.81
      Open
      50.73
      Last Trade
      98
      @
      47.19
      Last Trade Time
      Financial Volume
      $ 54,935,954
      VWAP
      50.1356
      Average Volume (3m)
      589,800
      Shares Outstanding
      68,210,479
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -
      Revenue
      43.95M
      Net Profit
      -154.94M

      About Merus NV

      Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

      Sector
      Gen Med & Surgical Hospitals
      Industry
      Gen Med & Surgical Hospitals
      Website
      www.merus.nl
      Headquarters
      Utrecht, Utrecht, Nld
      Founded
      -
      Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $50.81. Over the last year, Merus NV shares have traded in a share price range of $ 19.805 to $ 61.61.

      Merus NV currently has 68,210,479 shares outstanding. The market capitalization of Merus NV is $3.47 billion.

      Ask ADVFN Intelligence (AI)

      MRUS Latest News

      More News

      Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      September 17 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 22 2024
      Edgar (US Regulatory)

      Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

      August 06 2024
      GlobeNewswire Inc.

      Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

      – Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial...

      August 01 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 01 2024
      Edgar (US Regulatory)

      Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 24 2024
      GlobeNewswire Inc.

      Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 08 2024
      GlobeNewswire Inc.

      Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 01 2024
      GlobeNewswire Inc.

      Form 144 - Report of proposed sale of securities

      June 17 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.30.60765647154149.3751.3448.7862728650.25607634CS
      4-3.83-7.1588785046753.554.62548.1249216550.63602329CS
      12-10.28-17.147623019259.9561.2847.500158980053.32273456CS
      265.0211.243001119844.6561.6139.2777501551.56850908CS
      5224.6298.283433133725.0561.6119.80563882844.14874666CS
      15624.5197.416534181225.1661.6112.0342990733.34277663CS
      26030.47158.69791666719.261.6110.1831102930.73155612CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BNZIBanzai International Inc
      $ 5.645
      (96.01%)
      		61.39M
      ZJYLJin Medical International Ltd
      $ 3.975
      (50.00%)
      		1.24M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.9001
      (39.43%)
      		78.85k
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      AENTAlliance Entertainment Holding Corporation
      $ 2.74
      (34.31%)
      		4.23M
      GSIWGarden Stage Ltd
      $ 1.34
      (-82.89%)
      		26.44M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 19.51
      (-62.26%)
      		12.29M
      LGCBLinkage Global Inc
      $ 0.4183
      (-57.70%)
      		2.16M
      BFIBurgerFi International Inc
      $ 0.0855
      (-42.27%)
      		15.05M
      SKYESkye Bioscience Inc
      $ 3.17
      (-42.26%)
      		5.14M
      XPONExpion360 Inc
      $ 0.081
      (39.18%)
      		1.46B
      NVDANVIDIA Corporation
      $ 116.00
      (-1.59%)
      		378.16M
      AAPLApple Inc
      $ 228.20
      (-0.29%)
      		320.24M
      INTCIntel Corporation
      $ 21.84
      (3.31%)
      		261.68M
      VERBVerb Technology Company Inc
      $ 0.0742
      (33.45%)
      		178.65M

      MRUS Discussion

      View Posts
      Monksdream Monksdream 1 week ago
      MRUS range bound
      👍️0
      Phosphene Phosphene 4 years ago
      Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

      https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
      👍️0
      Phosphene Phosphene 4 years ago
      The Baker Brothers have 7% ownership.

      https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
      👍️0
      Phosphene Phosphene 4 years ago
      Board Member: Victor Sandor

      https://ir.merus.nl/board-member/victor-sandor

      https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
      👍️0
      Phosphene Phosphene 4 years ago
      Second Quarter 2020 Results:

      https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
      👍️0
      Phosphene Phosphene 4 years ago
      https://merus.nl/
      👍️0
      Phosphene Phosphene 4 years ago
      European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

      https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
      👍️0

      Your Recent History

      NASDAQ
      MRUS
      Merus NV
      Delayed Upgrade Clock